ClinicalTrials.gg
RecruitingNCT05334836FPPCNUpdated Oct 27, 2026

Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features

An interventional study of MRI for pancreatic fat and liver fat quantitation in Pancreatic Steatosis and Pancreatic Cyst, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Updated Oct 27, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers were diagnosed globally . Pancreatic cancer is a highly fatal cancer with a case-fatality rate of 94.0% globally. In Hong Kong, both the incidence and mortality of pancreatic cancer have increased over the past decade.

Due to the deep-seated location of pancreas, it is difficult to diagnose pancreatic cancer at an early stage, which in turn leads to delays in cancer treatment and poorer survival. Despite advances in oncologic treatment, the 5-year survival rate of metastatic pancreatic cancer remains poor (\~2.9%). As such, there has been growing interest to improve pancreatic cancer prevention and survival by:

  1. reduction of modifiable risk factors (eg, cigarette smoking, obesity, diabetes),
  2. screening for early detection of high-risk pre-malignant lesions in selected high-risks patients with strong family history of pancreatic cancer and/or certain germline mutations of pancreatic cancer susceptibility genes (eg, BRCA1, BRAC2, DNA mismatch repair genes in Lynch Syndrome, etc) by magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS), and
  3. surveillance of pre-malignant precursor lesions such as mucinous pancreatic cystic neoplasms (PCN) by imaging and/or EUS to identify high-risk neoplastic progression indicated for surgical resection.
Read the detailed description

Pancreatic cancer is the fifth leading cause of cancer mortality in Hong Kong and the seventh leading cause of cancer mortality worldwide. In 2020, approximately 496000 new cases of pancreatic cancers were diagnosed globally . Pancreatic cancer is a highly fatal cancer with a case-fatality rate of 94.0% globally. In Hong Kong, both the incidence and mortality of pancreatic cancer have increased over the past decade.

Due to the deep-seated location of pancreas, it is difficult to diagnose pancreatic cancer at an early stage, which in turn leads to delays in cancer treatment and poorer survival. Despite advances in oncologic treatment, the 5-year survival rate of metastatic pancreatic cancer remains poor (\~2.9%). As such, there has been growing interest to improve pancreatic cancer prevention and survival by:

  1. reduction of modifiable risk factors (eg, cigarette smoking, obesity, diabetes),
  2. screening for early detection of high-risk pre-malignant lesions in selected high-risks patients with strong family history of pancreatic cancer and/or certain germline mutations of pancreatic cancer susceptibility genes (eg, BRCA1, BRAC2, DNA mismatch repair genes in Lynch Syndrome, etc) by magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS), and
  3. surveillance of pre-malignant precursor lesions such as mucinous pancreatic cystic neoplasms (PCN) by imaging and/or EUS to identify high-risk neoplastic progression indicated for surgical resection

The prevalence of incidentally found pancreatic cystic lesions ranges from 2.1% to 13.5% in patients undergoing CT or MRI for non-pancreatic indications. In patients with pre-malignant mucinous PCN (intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN)), pancreatic cancer can originate from the pre-malignant PCN, or develop in other parts of the pancreas uninvolved by the original PCN due to "field-defect". While the malignant potentials of different PCNs vary, the frequency of invasive carcinoma and high-grade dysplasia in IPMN remains substantial, ranging from 36-100% in the main duct type (MD-IPMN) and from 14-48% in the branch duct type (BD-IPMN).

Multiple consensus guidelines and society guidelines have been developed based on cyst structural characteristics and cyst related symptoms to guide management between surgical resection or surveillance of pre-malignant PCN. The 2017 revised international consensus guidelines (Fukuoka guidelines) recommend surgical resection for all MD-IPMN and BD-IPMN with high-risk stigmata of malignancy or worrisome features confirmed by EUS (definite mural nodule > 5mm, main pancreatic duct involvement (dilation / abrupt change in calibre), cytology suspicious or positive for malignancy on EUS guided fine needle aspiration). On the other hand, surveillance of asymptomatic BD-IPMN without high-risk stigmata or worrisome features would be performed with cross-sectional imaging and/or EUS periodically, with intervals tailored to the size of the BD-IPMN.

Although the consensus guidelines and society guidelines have been widely applied in clinical practice, considerable variations in their sensitivity, specificity, positive and negative predictive values in predicting advanced neoplasia (high-grade dysplasia and invasive cancer) in pre-malignant PCN were reported in validation studies. As such, false-positive (recommending patients with low-risk PCN for a major surgery with considerable risks of morbidity/ mortality) or false-negative (missing a high-risk PCN with indication for surgery to prevent cancer development) prediction of malignant progression of mucinous PCN can still occur with significant clinical ramification. In addition, while cyst structural characteristics are traditional risk factors for neoplastic progression of PCN, these are not easily modifiable unless invasive procedures such as surgical resection or cyst ablation is performed. Therefore, it is of clinical importance to identify novel risk factors in pancreas that are potentially modifiable and may improve the current risk stratification algorithm for detection of high-risk lesions.

Pancreatic steatosis is an increasingly recognized important metabolic condition with a prevalence of 16% to 35% in Asian populations. Recent retrospective studies have suggested an increased risk of pancreatic cancer, IPMN and progression of BD-IPMN in patients with pancreatic steatosis. However, despite its potential role as a modifiable risk factor for pancreatic cancer and progression of pre-malignant PCN such as IPMN, the actual prevalence of pancreatic steatosis in patients with PCN is not known.

While ultrasound, CT and MRI have been used for fat quantitation in organs, MRI is best suited for this purpose since its signal is dependent on fat content. In contrast to fat content assessment by ultrasound in which interobserver variability may undermine its reliability, the fat fraction measurements by MRI are reproducible and accurate, and have been validated against histology in animal models. In addition, MRI also has an advantage over CT since there is no risk of radiation exposure.

Previous work by our group has defined the normal range of fat content in pancreas (1.8% -10.4%) in the healthy Hong Kong population using MRI for fat quantification. The prevalence of fatty pancreas in healthy volunteers was found to be 16.1% when a pancreatic fat upper limit of normal of 10.4% was adopted. Our group has also shown that patients with fatty liver do not always have fatty pancreas. Among the 195 patients with fatty liver in our prior study, 82/195 (42.1%) had both fatty liver and fatty pancreas and 113/195 (57.9%) had fatty liver alone. Such observation suggested that pancreatic steatosis is likely a separate metabolic condition that deserves further investigation for its potential impact on important pancreatic pathologies such as pre-malignant PCN (eg, IPMN) and pancreatic cancer.

Because little is known about the prevalence of pancreatic steatosis in patients with PCN, we would like to propose a prospective, matched case-control study to determine the prevalence of pancreatic steatosis using MRI in patients with presumed IPMN or MCN and compare with that of age and sex matched healthy subjects in the general population.

02

Conditions studied

  • Pancreatic Steatosis
  • Pancreatic Cyst

Browse trials for

03

In context

Pancreatic Cyst

97 studies on the registry are indexed under Pancreatic Cyst; 37 are open to participants now.

This study's planned enrollment of 236 is above the median of 84 across 38 interventional studies indexed under Pancreatic Cyst.

Browse Pancreatic Cyst studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 or older
  2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects.
  3. Patients who are able to provide written to participate in the study and comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Unable to provide written
  2. Patients with metallic implants or other to MRI
  3. Patients with contraindications for endoscopy due to comorbidities
  4. Patients with known pancreatic cancer or prior pancreatic resection
  5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Active comparator
    Pancreatic cystic lesion subjects

    Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm

    Diagnostic Test: MRI for pancreatic fat and liver fat quantitation

  • Active comparator
    Healthy subjects

    Healthy subjects

    Diagnostic Test: MRI for pancreatic fat and liver fat quantitation

Interventions

  • Diagnostic testMRI for pancreatic fat and liver fat quantitation

    MR imaging would be performed using a 3.0 T scanner (Achieva X series, Philips Healthcare, Best, The Netherlands) with a 16-channel SENSE-XL-Torso array coil. 3D spoiled chemical-shift water-fat mDixon sequence (TR = 5.7 ms, first TE/echo spacing = 1.2-1.4 (ms)/1.0-1.2 (ms), number of echoes = 6, flip angle = 3°, SENSE acceleration = 2, a breath hold technique would be employed to acquire co-registered water, fat, fat-fraction and T2\* image series and would be reconstructed with slice thickness/number of slices = 3.0 mm/50. The field of view (FOV) covered the upper abdomen, i.e. region from the dome of the diaphragm to the iliac crest covering the entire extent of the liver and pancreas. Image reconstruction would be completed online using Philips mDixon product implementation with the multi-peak spectral model of fat to increase accuracy and sensitivity.

06

What researchers measure

Primary outcomes

  1. Prevalence of pancreatic steatosis determined by fat quantitation on MRI

    Prevalence of pancreatic steatosis will be determined in patients with presumed IPMN or MCN and in age and sex matched healthy subjects in the general population.

    Time frame: At the time of procedure

Secondary outcomes

  1. Prevalence of worrisome features or high-risk stigmata on baseline EUS in patients with presumed IPMN or MCN and pancreatic steatosis

    worrisome features or high-risk stigmata are defined according to 2017 revised Fukuoka international consensus guidelines

    Time frame: At the time of procedure

  2. Prevalence of worrisome features or high-risk stigmata on baseline EUS in patients with presumed IPMN or MCN without pancreatic steatosis

    worrisome features or high-risk stigmata are defined according to 2017 revised Fukuoka international consensus guidelines

    Time frame: At the time of procedure

  3. Prevalence of coexisting fatty liver and fatty pancreas, fatty liver alone, or fatty pancreas alone in patients with presumed IPMN or MCN

    Diagnosis of fatty liver, fatty pancreas will be based on fat quantitation on MRI

    Time frame: At the time of procedure

  4. Risk factors for pancreatic steatosis in patients with presumed IPMN or MCN

    Regression analysis will be used to help identify risk factors for pancreatic steatosis

    Time frame: At the time of procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2027, 60 months after the start.

Of 17 interventional studies with no phase under Pancreatic Cyst, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 64. This study's planned 60 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Apr 2026 → Apr 2027 and completion Apr 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 19, 2022
StartActual
Apr 6, 2022
Primary completionEst.
Apr 30, 2027was Apr 2026
CompletionEst.
Apr 30, 2027was Apr 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 30, 2026→Apr 30, 2027
Oct 27, 2026
Study completion
Apr 30, 2026→Apr 30, 2027
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Apr 30, 2026→Apr 30, 2027
    Study completion Apr 30, 2026→Apr 30, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05334836
Responsible party
Raymond Shing Yan Tang (Assitant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Apr 19, 2022
Start date
Apr 6, 2022
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Felix Sia
Contact
felixsia@cuhk.edu.hk
26370428
Raymond S Tang, MD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion